SCHEMBL1677478

SCHEMBL1677478

O=[N+]([O-])c1cc(S(=O)(=O)Nc2ncnc3cc(N4CCN(Cc5ccccc5-c5ccccc5)CC4)ccc23)ccc1N[C@@H](CCN1CCOCC1)CSc1ccccc1

nearest known ligand 0.93

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 18/20 0.93
BCL2 P10415 15/20 0.93
BCL2L2 Q92843 3/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1677481 1.00 BCL2L1 (0.93) BCL2L1BCL2BCL2L2
SCHEMBL1677971 0.96 BCL2L1 (0.90) BCL2L1BCL2BCL2L2
SCHEMBL1677388 0.96 BCL2 (1.00) BCL2L1BCL2BCL2L2
SCHEMBL1678298 0.96 BCL2L1 (0.90) BCL2L1BCL2BCL2L2
SCHEMBL1677965 0.96 BCL2L1 (0.90) BCL2L1BCL2BCL2L2
SCHEMBL1678299 0.96 BCL2L1 (0.90) BCL2L1BCL2BCL2L2
SCHEMBL1677390 0.96 BCL2 (1.00) BCL2L1BCL2BCL2L2
SCHEMBL1678124 0.95 BCL2L1 (0.88) BCL2L1BCL2BCL2L2
SCHEMBL1678118 0.95 BCL2L1 (0.88) BCL2L1BCL2BCL2L2
SCHEMBL1679029 0.95 BCL2L1 (0.87) BCL2L1BCL2BCL2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098305-A1 ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE BAELL JONATHAN BAYLDON 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098305-A1 ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE BAX, API5, BCL2 BCL2L1 13/4885BCL2 3/4885BCL2L2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.